Drugs / AK001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02563938 | Sep 2015 → Mar 2016 | atopic IgE-mediated allergic disorder | Allakos Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02734849 | Apr 2016 → Jan 2018 | nasal cavity polyp | Allakos Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-10-17 | RemeGen Co., Ltd. | Results IGCS 2024 | Results of Disitamab Vedotin Combined with Cadonilimab for Cervical Cancer First Announced with ORR up to 50% remegen.com ↗
At the meeting, the result of a phase 2 clinical study on Disitamab Vedotin combined with Cadonilimab to treat recurrent or metastatic cervical cancer (AK001) was published for the first time, drawing much attention. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-10-17 | RemeGen Co., Ltd. | IGCS 2024 | Results of Disitamab Vedotin Combined with Cadonilimab for Cervical Cancer First Announced with ORR up to 50% remegen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02734849 ↗ |
| Modality | Monoclonal antibody | “AK001 is a monoclonal antibody” NCT02563938 ↗ |